B cell treatments for multiple sclerosis

Excerpt

The established picture of immunological dysfunction in Multiple Sclerosis (MS) posits a central role for T cells. As a consequence, the development of disease-modifying treatments (DMTs) has been targeted at sequestering, lysing or depressing production of T cells. This approach has been generally successful in reducing relapses and surrogate imaging markers of diseases activity, but has not been so effective in delaying the onset of progressive disease, and/or disability accumulation. In addition response to even high efficacy treatments is often not complete and there remain small groups of non-responders suggesting a degree of biological diversity. As a result much remains to be achieved in the field of MS therapeutics. …